These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent. Van de Weert-van Leeuwen PB; Van Meegen MA; Speirs JJ; Pals DJ; Rooijakkers SH; Van der Ent CK; Terheggen-Lagro SW; Arets HG; Beekman JM Am J Respir Cell Mol Biol; 2013 Sep; 49(3):463-70. PubMed ID: 23617438 [TBL] [Abstract][Full Text] [Related]
23. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease. Fernandez Fernandez E; De Santi C; De Rose V; Greene CM Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581 [TBL] [Abstract][Full Text] [Related]
24. Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. Polineni D; Dang H; Gallins PJ; Jones LC; Pace RG; Stonebraker JR; Commander LA; Krenicky JE; Zhou YH; Corvol H; Cutting GR; Drumm ML; Strug LJ; Boyle MP; Durie PR; Chmiel JF; Zou F; Wright FA; O'Neal WK; Knowles MR Am J Respir Crit Care Med; 2018 Jan; 197(1):79-93. PubMed ID: 28853905 [TBL] [Abstract][Full Text] [Related]
26. HCO3- transport in relation to mucus secretion from submucosal glands. Joo NS; Krouse ME; Wu JV; Saenz Y; Jayaraman S; Verkman AS; Wine JJ JOP; 2001 Jul; 2(4 Suppl):280-4. PubMed ID: 11875272 [TBL] [Abstract][Full Text] [Related]
27. Proteomics investigation of human platelets in healthy donors and cystic fibrosis patients by shotgun nUPLC-MSE and 2DE: a comparative study. Pieroni L; Finamore F; Ronci M; Mattoscio D; Marzano V; Mortera SL; Quattrucci S; Federici G; Romano M; Urbani A Mol Biosyst; 2011 Mar; 7(3):630-9. PubMed ID: 21072441 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Roomans GM Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993 [TBL] [Abstract][Full Text] [Related]
30. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449 [TBL] [Abstract][Full Text] [Related]
31. A sheep model of cystic fibrosis generated by CRISPR/Cas9 disruption of the CFTR gene. Fan Z; Perisse IV; Cotton CU; Regouski M; Meng Q; Domb C; Van Wettere AJ; Wang Z; Harris A; White KL; Polejaeva IA JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282831 [TBL] [Abstract][Full Text] [Related]
33. Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill. Boucher RC; Knowles MR; Johnson LG; Olsen JC; Pickles R; Wilson JM; Engelhardt J; Yang Y; Grossman M Hum Gene Ther; 1994 May; 5(5):615-39. PubMed ID: 7519885 [TBL] [Abstract][Full Text] [Related]
34. EG-VEGF, BV8, and their receptor expression in human bronchi and their modification in cystic fibrosis: Impact of CFTR mutation (delF508). Chauvet S; Traboulsi W; Thevenon L; Kouadri A; Feige JJ; Camara B; Alfaidy N; Benharouga M Am J Physiol Lung Cell Mol Physiol; 2015 Aug; 309(3):L314-22. PubMed ID: 26047640 [TBL] [Abstract][Full Text] [Related]
35. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease. Mall MA Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118 [TBL] [Abstract][Full Text] [Related]
36. Cellular heterogeneity of CFTR expression and function in the lung: implications for gene therapy of cystic fibrosis. Jiang Q; Engelhardt JF Eur J Hum Genet; 1998 Jan; 6(1):12-31. PubMed ID: 9781011 [TBL] [Abstract][Full Text] [Related]
37. Cystic Fibrosis: Pathophysiology of Lung Disease. Bergeron C; Cantin AM Semin Respir Crit Care Med; 2019 Dec; 40(6):715-726. PubMed ID: 31659725 [TBL] [Abstract][Full Text] [Related]
38. Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms. Noel S; Panin N; Beka M; Dhooghe B; Huaux F; Leal T Clin Sci (Lond); 2017 Jun; 131(11):1107-1121. PubMed ID: 28196856 [TBL] [Abstract][Full Text] [Related]
39. Expression and function of Anoctamin 1/TMEM16A calcium-activated chloride channels in airways of in vivo mouse models for cystic fibrosis research. Hahn A; Salomon JJ; Leitz D; Feigenbutz D; Korsch L; Lisewski I; Schrimpf K; Millar-Büchner P; Mall MA; Frings S; Möhrlen F Pflugers Arch; 2018 Sep; 470(9):1335-1348. PubMed ID: 29860639 [TBL] [Abstract][Full Text] [Related]
40. Electrolyte transport properties in distal small airways from cystic fibrosis pigs with implications for host defense. Li X; Tang XX; Vargas Buonfiglio LG; Comellas AP; Thornell IM; Ramachandran S; Karp PH; Taft PJ; Sheets K; Abou Alaiwa MH; Welsh MJ; Meyerholz DK; Stoltz DA; Zabner J Am J Physiol Lung Cell Mol Physiol; 2016 Apr; 310(7):L670-9. PubMed ID: 26801568 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]